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Key Points
• Optimal treatments for functional constipation (FC) and irritable bowel syndrome with constipation (IBS-C)
differ, but symptom criteria do not reliably distinguish between them; some regard FC and IBS-C as parts of a
single constipation spectrum.
• Physiological studies show modest support for the hypothesis that decreased colonic motility and prolonged
whole gut transit identify FC while pain hypersensitivity distinguishes IBS-C, but there is substantial overlap.
Pelvic floor dyssynergia appears to be unrelated to symptom patterns in FC or IBS-C.
• A novel magnetic resonance imaging technique seems to reliably distinguish FC from IBS-C based on the
response to an osmotic laxative.
Abstract
Treatments for functional constipation (FC) and irri-
table bowel syndrome with constipation (IBS-C) dif-
fer, but symptom criteria do not reliably distinguish
between them; some regard FC and IBS-C as parts of a
single constipation spectrum. Our goal was to review
studies comparing FC and IBS-C to identify possible
biomarkers that separate them. A systematic review
identified 15 studies that compared physiologic tests
in FC vs IBS-C. Pain thresholds were lower in IBS-C
than FC for 3/5 studies and not different in 2/5.
Colonic motility was decreased more in FC than IBS-
C for 3/3 studies, and whole gut transit was delayed
more in FC than IBS-C in 3/8 studies and not different
in 5/8. Pelvic floor dyssynergia was unrelated to
diagnosis. Sympathetic arousal, measured in only
one study, was greater in IBS-C than FC. The most
reliable separation of FC from IBS-C was shown by a
novel new magnetic resonance imaging technique
described in this issue of the journal. These authors
showed that drinking one liter of polyethylene glycol
laxative significantly increased water content in the
small intestine, volume of contents in the ascending
colon, and time to first evacuation in FC vs IBS-C; and
resulted in less colon motility and delayed whole gut
transit in FC compared to IBS-C. Although replication
is needed, this well-tolerated, non-invasive test pro-
mises to become a new standard for differential
diagnosis of FC vs IBS-C. These data suggest that FC
and IBS-C are different disorders rather than points on
a constipation spectrum.
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The study in this issue of Neurogastroenterology
and Motility by the Nottingham group 1 may be
remembered as a turning point in the controversy over
whether FC and IBS-C are two distinct disorders or
parts of a spectrum of symptoms related to a shared
pathophysiology. This study was able to show signif-
icant differences between well-characterized groups of
patients with FC and IBS-C in whole gut transit time,
colonic motility, water content in the small intestine,
and colon volumes using validated, novel, non-inva-
sive magnetic resonance imaging (MRI) techniques.
The authors suggest that these are biomarkers for the
differential diagnosis of subtypes of constipation.
Future research may make it possible to individualize
treatment based on these biomarkers.
Some of the unique strengths of this study and of the
MRI techniques described are listed below:
1. These MRI-based physiological tests are better
accepted by patients than are traditional physiolog-
ical tests, such as pressure measurements made
with intraluminal motility catheters, barostat bal-
loons, abdominal radiographs of the transit of
radiopaque markers, or gamma cameras, to assess
the progression of radioisotopes. Because these MRI
investigations are better tolerated, they are less
likely to bias the data due to the unwillingness of
some patients to undergo invasive testing or their
apprehension during the tests.
2. The investigators assessed the physiological
response to a standardized provocative stimulus,
namely the ingestion of a liter of an osmotic laxative
consisting of polyethylene glycol and electrolytes in
a commercially available preparation. This mini-
mizes measurement error due to variability in
physiological responses from day to day, which
may confound purely observational studies.
3. TheseMRI-based tests of transit, motility, and volume
of water in the small bowel and colon were all
previously validated in normal controls with the result
that normal ranges and reproducibility are known.2–6
Moreover, the sensitivity ofMRImeasures of colon and
small bowel volumes has been shown by comparing
the effects of ingesting different food types on the
volume and distribution of gas and water in the gut.7
SYMPTOM-BASED CLASSIFICATION OF
CONSTIPATION SUBTYPES
Constipation is a symptom (not a disease), which may
present in several different phenotypes. The Rome III
criteria8 rely on history and symptoms to distinguish
between two major categories of constipation: IBS-C
and FC. Patients are classified as IBS-C if they have
abdominal pain at least 3 days a month in addition to
symptoms of constipation, or as FC if they have at least
two of six symptoms of difficult or infrequent defeca-
tion occurring 25% of the time and insufficient pain to
qualify for a diagnosis of IBS. The Rome III criteria did
not permit a patient who met criteria for IBS-C to be
diagnosed with comorbid FC, that is, overlap between
IBS-C and FC was not permitted. The recently released
update to the Rome diagnostic criteria (Rome IV)9
make no significant changes to the diagnostic criteria
for IBS-C and FC; although the experts that reviewed
and updated the Rome diagnostic criteria concluded,
based on a review of recent new data, that IBS-C and FC
are probably different parts of a spectrum of symptoms
of constipation rather than distinct disorders, they did
not modify the Rome III approach of classifying these
as independent, and mutually exclusive diagnoses.
The pivotal study which led the Rome IV bowel
committee to re-evaluate the distinction between IBS-
C and FC was reported by Wong and colleagues.10
These investigators administered the Rome III Diag-
nostic Questionnaire to 1707 adult patients in a large
health maintenance organization. The symptom sur-
vey was administered on two occasions 12 months
apart. Using the Rome III criteria, they identified 231
patients with FC and 201 with IBS-C in the initial
survey. Key findings were: (i) When the Rome III (also
the Rome IV) requirement that patients meeting crite-
ria for IBS-C cannot also be diagnosed FC was sus-
pended, 90% of IBS-C cases met criteria for FC and 44%
of FC cases met criteria for IBS-C. (ii) When the official
Rome III criteria were again employed, there were no
qualitative differences between FC and IBS-C: 45% of
FC patients reported some abdominal pain, and the IBS-
C patients were found to have more symptoms of
difficult or infrequent defecations than the FC patients.
(iii) When the patients diagnosed as FC or IBS-C were
reassessed 1 year later, 1/3 of patients in each group
Current symptom criteria do not reliably distinguish 
between functional constipation (FC) and irritable 
bowel syndrome with constipation (IBS-C), and some 
investigators regard them as parts of a single constipa-
tion spectrum. However, some treatments are thought 
to work better for one of these types of constipation 
than the other, so it is important to know whether 
there are ways of reliably distinguishing between 
them. Moreover, it is important to know whether 
there are different pathophysiological mechanisms 
accounting for these two types of constipation because 
they may represent different targets for drug develop-
ment. Our goal was to review studies comparing 
groups of patients diagnosed FC and IBS-C to identify 
possible biomarkers that separate them.
aborally propagating contractions.19 However, intesti-
nal motility is difficult to measure directly, so the time
required for transit of indigestible markers or radioiso-
topes is used as a surrogate marker of abnormal
intestinal motility. The hypothesis is that prolonged
whole gut transit should discriminate FC from IBS-C.
Pelvic floor dysfunction
The symptom of difficult evacuation of stool from the
rectum is often attributed to one of twomechanisms: (i)
paradoxical contraction or failure to relax the pelvic
floor muscles, and/or (ii) inadequate increases in rectal
pressure (i.e., a negative rectal-to-anal canal pressure
gradient) during attempts to defecate. Many terms have
been used to characterize this phenomenon (e.g., anis-
mus, pelvic floor dyssynergia, dyssynergic defecation),
but the Rome IV criteria use the umbrella term, func-
tional defecation disorder, to refer to difficult defecation
from either cause, and they distinguish two subtypes
based on which one of two mechanisms is in play:
dyssynergic defecation or inadequate rectal propul-
sion.20 Dyssynergic defecation and inadequate rectal
propulsion are usually assessed by anorectalmanometry
or by pelvic floor electromyography (EMG). The balloon
evacuation test is a measure of the time required for
subjects to evacuate a water- or air-filled balloon from
the rectum, and it is regarded as ameasure of pelvic floor
dysfunction.21 Our hypothesis is that functional defe-
cation disorder is a subtype of FC and that the physio-
logical measures referred to above (anal canal pressure,
pelvic floor EMG, intra-abdominal pressure during
efforts to evacuate and the balloon evacuation test)
shoulddiscriminate patientswithFC frompatientswith
IBS-C.However, we acknowledge that there is currently
some controversy over whether functional defecation
disorder is more closely linked to IBS-C than to FC.22
Other pathophysiological mechanisms for
constipation
Additional physiological risk factors have been pro-
posed for the symptom of constipation including the
side-effects of opiate or anticholinergic medications,
inadequate fiber and water in the diet, and decreased
intestinal secretion. However, this discussion will
focus on the three mechanisms listed above.
REVIEW OF STUDIES COMPARING IBS-C
TO FC
Table 1 and Fig. 1 summarize the 15 studies identified
by a systematic search of PubMed using the terms
switched to the other diagnosis if they continued to 
have symptoms of constipation. Wong and colleagues 
concluded that patients identified by the Rome III 
criteria as FC and IBS-C are not distinct groups. Several 
other studies reached similar conclusions.11
Other evidence12 suggests that practicing gastroen-
terologists may not regard FC and IBS-C as mutually 
exclusive diagnoses: We sought to validate the Rome IV 
criteria for FC by comparing the clinical diagnoses of 
experienced gastroenterologists from nine sites with the 
diagnoses assigned to their patients based on the Rome IV 
Diagnostic Questionnaire completed by the patient 
independently following their clinic visit. When the 
Rome IV requirement that FC could not be diagnosed if 
the patient fulfilled Rome IV criteria for IBS was 
followed, only 32% of patients who received a clinical 
diagnosis of FC were classified FC by the Rome IV 
criteria. However, if overlap between IBS-C and FC was 
allowed, 73% of clinically diagnosed patients with 
chronic constipation fulfilled the Rome IV criteria for FC.
PATHOPHYSIOLOGICAL MECHANISMS 
FOR THE SYMPTOMS OF IBS AND FC
Pain sensitivity
The defining symptom of IBS, and the symptom which 
distinguishes IBS-C from FC according to the Rome IV 
criteria,9 is abdominal pain. As a group, IBS patients have 
increased visceral pain sensitivity as reflected in a lower 
threshold of rectal or colonic distension to report pain 
(allodynia)13–17 and a greater intensity of pain for a 
specified level of colorectal distention within the noxious 
range (hyperalgesia).17,18 However, there is an overlap 
between IBS patients and healthy controls in pain 
sensitivity, and the correlation between the pain thresh-
old and the frequency and intensity of clinically reported 
abdominal pain is modest.15,17 One explanation for this 
modest correlation between physiological measures of 
pain sensitivity and symptoms of abdominal pain is that 
increased sensitivity requires a distention stimulus such 
as accumulated stool or gas to trigger an actual pain 
sensation in a pain sensitive subject. Nevertheless, we 
would expect increased visceral pain sensitivity to 
discriminate patients with IBS-C from those with FC.
Delayed whole gut transit
The mechanism that is believed to account for infre-
quent passage of stools is impaired peristaltic motility 
in the colon or small intestine due to decreased 
amplitudes and/or non-peristaltic patterns of contrac-
tions and/or deficient numbers of high-amplitude
Table 1 Summaries of studies comparing FC to IBS-C
Study Population Measures Results
Mertz23,24 131 patients with refractory
constipation including 107 (82%)
who met criteria for IBS.
Physiological data were not
analyzed by Rome diagnoses, but
by symptom clusters derived from
principal components analysis.
Symptom checklist, WGT (Sitzmark
transit test); PainTh by barostat;
DYS by anorectal manometry and
EMG combined
Delayed WGT, visceral hypersensitivity, and
DYS frequently overlaped but were not
significantly correlated. Factor analysis
identified four symptom clusters: IBS-C,
slow transit constipation (STC), functional
defecation disorder, and normal transit.
IBS-C correlated with discomfort threshold
and STC symptom cluster correlated with
WGT, but FDD cluster of symptoms did
not correlate with DYS.
Bouin16 86 IBS (all subtypes), 26 FC, 21
Functional Dyspepsia, 31
miscellaneous FGIDs, 25 HV
PainTh: Progressively larger
intermittent phasic distentions by
barostat. Calculated sensitivity,
specificity, and PPV of
discriminating between groups.
PainTh: Best discrimination of IBS from all
other FGID patients and from HV was
40 mmHg. Sensitivity = 95.5%,
specificity = 71.8%, PPV = 85.4%
Bassotti19 35 STC, 10 IBS-C, 18 HV Motility: High amplitude propagated
contractions (HAPC)/24 h; Low
amplitude propagated contractions
(LAPC)/24 h, response to meal
Motility: STC and IBS-C had fewer HAPCs
than HV (1.5 vs 3.7 vs 6.0). STC had fewer
LAPCs than IBS-C (46 vs 87.4). Meal
stimulated LAPCs in all three groups.
Walter25 27 IBS (most with loose stools),
13 FC, 18 HV
Sympathetic activity: Skin
conductance (SC) measured on foot.
Phasic distentions by barostat to
determine thresholds for first
sensation, urge, and maximum
tolerable volume; and habituation
of SC response to repeated
distentions
Sympathetic activation: At baseline SC
higher in IBS vs HV and lower in FC vs HV.
All sensory thresholds were lower in IBS-C
than in FC. SC response to distention was
higher in IBS vs HV and habituated
over trials.
Hasler26 12 IBS-C, 24 FC, 53 HV Motility: Number of contractions
measured by wireless motility
capsule
Motility: IBS-C had more contractions than
FC or HV. FC was not significantly
different from HV.
Suttor27 29 FDD + IBS, 21 FDD – IBS WGT; DYS assessed by ARM; BET;
PainTh: sensory thresholds;
response to biofeedback
WGT: no difference between groups;
PainTh: no difference; BET: no difference;
DYS: no difference; response to
biofeedback: no difference but IBS
symptoms improved after pelvic floor
biofeedback
Ansari28 25 FC vs 25 non-diarrhea
predominant IBS
DYS; BET DYS: more prevalent in FC than IBS; BET:
more abnormalities in IBS than FC
Patcharatrakul29 50 FC vs 50 IBS-C WGT, segmental transit time WGT: no significant difference but a trend
with 52.2 h for FC and 41.2 h for IBS-C;
rectosigmoid transit slower for FC than IBS-
C (19.9 h vs 11.9 h)
Bouchoucha30 50 HV, 43 FC, 46 IBS-C, 15
IBS-M, 13 IBS-D, 10 FD
Fasting WGT, change in WGT before
to after 1000 cal meal, meal-related
symptoms
WGT: slower in FC than IBS-C (84.1 h vs
49.4 h). Minimal differences in response to
eating
Shekhar31 11 FC, 23 IBS-C, 23 HV WGT; SBTT; PaintTh; plasma 5-HT WGT: no difference between IBS-C and FC;
both greater than HV. PainTh: IBS-C lower
than FC or HV. 5-HT: IBS-C lower than FC
or HV.
Bouchoucha32 66 IBS-C, 62 FC WGT, segmental transit time; DYS;
discomfort threshold
WGT: no significant difference (71 h for FC
vs 60 h for IBS-C). DYS: more frequent in
IBS-C (56% vs 37%). PainTh: no difference
between FC vs IBS-C (238 mL vs 241 mL).
Park33 88 FC, 57 IBS-C WGT; gas volume in colon WGT: no significant difference between IBS-
C and FC (38.4 h vs 43.8 h). Gas volume:
no difference between FC and IBS-C.
Bouchoucha34 210 IBS-C, 194 FC WGT; ‘difficult defecation’ defined
by >2 symptoms of straining,
incomplete evacuation, anal
blockage, digital maneuvers
WGT: no difference overall between FC and
IBS-C (59.4 h vs 58.6 h). Symptoms of
difficult defecation: more frequent in IBS-C
(84%) than FC (68%). In FC but not IBS-C,
patients with difficult defecation
symptoms had slower WGT than those
without (61.5 h vs 50.9 h).
(Continued.)
dyssynergic defecation or outlet dysfunction or anis-
mus). We screened titles and then abstracts to identify
articles of relevance to the topic. A requirement was
that the study had to directly compare separate patient
groups with FC or IBS-C. The search was not limited to
Table 1 (continued)
Study Population Measures Results
Lam1 24 FC, 24 IBS-C WGT by MRI marker, Motility by
variability in luminal diameter,
bloating sensitivity, small bowel
water content; colonic volumes. All
measured at baseline and following
1 L of Moviprep
WGT: Slower in FC than IBS-C; Motility:
less in FC vs IBS-C; Time to first
defecation: longer in FC vs IBS-C; Visceral
sensitivity to bloating: no difference; Small
bowel water content and ascending colonic
volume: greater for FC than IBS-C.
FC, functional constipation; IBS, irritable bowel syndrome; IBS-C, irritable bowel syndrome with constipation; FDD, functional defecation disorder;
STC, slow transit constipation; FGID, functional gastrointestinal disorder; HV, healthy volunteers; ARM, anorectal pressure measurements; BET,
balloon evacuation test; WGT, whole gut (i.e., mouth to anus) transit time; DYS, dyssynergic defecation (defined by paradoxical contraction when
pushing to evacuate and measured by anorectal manometry or electromyography); PainTh, rectal threshold pressure or volume for pain or discomfort;
SBTT, small bowel transit time; MRI, magnetic resonance imaging; SC, skin conductance (a measure of sympathetic arousal); 5-HT, 5-
hydroxytryptamine (serotonin).









Delayed whole gut transit
Colonic hypomotility
 Ascending colonic volume
 Small bowel water content
Dyssynergic defecation
Moderate Moderate
Strength of association between pathophysiology findings and diagnosis
Weak Weak
Figure 1 Schematic drawing demonstrating the symptom-based spectrum of functional constipation and irritable bowel syndrome with constipation,
and biomarkers that may be used to discriminate these conditions from each other. For further details, please see text.
(functional constipation or chronic constipation or 
idiopathic constipation) and (irritable bowel syndrome 
or IBS) and (physiological mechanism, or whole gut 
transit or Sitzmarks or motility or visceral hypersen-
sitivity or biomarker or disordered defecation or
Costeido et al.35 reported elevated synthesis and
release of 5-HT in FC, in contrast to a previous study
from this group36 which reported decreased 5-HT and
SERT in IBS-C. These authors suggest that there may
be increased 5-HT availability in the lamina propria in
both types of constipation, although the mechanisms
differ: increased synthesis in FC, and decreased clear-
ance in IBS-C. However, other studies37 have reported
different findings, so 5-HT signaling pathways cannot
yet be regarded as a reliable biomarker separating FC
from IBS-C.
Correlations between biomarkers
The study design in 14 of the 15 studies reviewed is
problematic because physiological findings were com-
pared between groups of patients who were classified
as FC or IBS-C on the basis of symptom criteria, and
symptom criteria have been shown to be unreliable for
classification of patients into these groups.11 Only one
study used a design that avoids this confounding factor:
Mertz and colleagues23 recruited 131 patients referred
for refractory constipation and assessed multiple phys-
iological measures in all of them. If FC and IBS-C are
on a spectrum but have a shared pathophysiology, one
might expect to find a positive correlation between
pain sensitivity and transit time or dyssynergia, but
instead the investigators found these biomarkers to be
uncorrelated and independent of each other. There
were groups of patients in whom these biomarkers
overlapped, but the frequency with which this
occurred was no greater than expected by chance.
DISCUSSION
The purpose of our review was to determine whether
the physiological mechanisms that have been proposed
for IBS and the two major subtypes of constipation
(slow transit constipation and functional defecation
disorder) can be regarded as biomarkers that identify
distinct groups of patients corresponding to IBS-C and
FC. The physiological markers investigated were pain
sensitivity, colonic motility (measured by whole gut
transit or different techniques to measure colonic
contractions), pelvic floor dyssynergia or inadequate
rectal propulsion pressure during attempted defecation,
and the balloon evacuation test. As is evident from
Table 1, the literature does not provide an unambigu-
ous answer to this question. There is heterogeneity of
findings among the studies with some showing the
expected associations between visceral pain hypersen-
sitivity and IBS-C, and between delayed transit or
English language publications, but all the studies 
meeting inclusion criteria were published in English.
Whole gut transit and motility
Eight studies in Table 1 compared whole gut transit 
(WGT) in FC vs IBS-C. The hypothesis was that transit 
time would be slower in FC than in IBS-C, and this was 
found in 3/8 studies.1,29,30 In five other studies27,31–34 
there was no statistically significant difference between 
FC and IBS-C, even though some of these studies found 
trends of differences between the groups in the expected 
direction. There were no studies that showed slower 
transit in IBS-C compared to FC, which suggests that 
there is a trend favoring the hypothesis. Motility of the 
colon was measured in three studies,1,19,26 and all three 
showed less motility in FC compared to IBS-C, which 
was the hypothesized outcome.
Pain thresholds
Visceral pain sensitivity was measured in four stud-
ies,16,27,31,32 and maximum tolerable volume was 
measured in one study.25 Three studies showed the 
expected lower pain threshold in IBS-C compared to 
FC.16,25,31 None of these five studies showed lower pain 
thresholds in FC compared to IBS-C, again suggesting 
a trend that favors the hypothesis of a specific associ-
ation between visceral pain sensitivity and IBS.
Dyssynergic defecation
This was measured in three studies: Dyssynergic 
defecation was more prevalent in FC than in IBS-C, 
as hypothesized, for one study,28 but was no different 
in one study27 and was paradoxically more prevalent in 
IBS-C than in FC in the third study.32 The balloon 
evacuation test, which is an alternative measure 
believed to reflect functional defecation disorder, was 
tested in two studies: there was no difference between 
IBS-C and FC in one of these studies,27 and abnormal 
balloon evacuation was unexpectedly more common in 
IBS-C than in FC in the other study.28 Thus, there is no 
apparent trend favoring the hypothesis that dyssyner-
gic defecation or inability to evacuate a simulated stool 
should be more common in FC compared to IBS-C.
Serotonin signaling
The Shekhar study31 found plasma 5-HT levels to be 
lower in IBS-C compared to FC. Other studies which 
measured serotonin in mucosal biopsies likewise sug-
gest that serotonin signaling differs in FC vs IBS-C:
consistent with the speculation of some authors that
dyssynergic defecation can give rise to symptoms that
are indistinguishable from IBS-C, namely rectal pain or
discomfort that is relieved by defecation.27,38 Other
investigators have found that pelvic floor dyssynergia
is not only seen in patients with difficult evacuation
but is also found in healthy controls.39,40 However, we
have previously shown that the presence of dyssyner-
gic defecation in patients meeting criteria for FC is a
strong predictor of which patients will benefit from
biofeedback therapy to teach patients how to relax the
pelvic floor during attempted defecation.41,42 This
remains an unresolved question which will require
additional research.
Future studies investigating whether IBS-C and FC
are distinct disorders or parts of a spectrum of symp-
toms with a shared pathophysiology should consider
the following alternative study designs: (i) Assess all
physiological mechanisms for abdominal pain and/or
constipation in the same patients regardless of whether
they meet a priori symptom criteria for IBS-C or FC,
and then look for objective evidence of overlap in the
physiological basis for these symptoms. This is the
approach pioneered by Mertz et al.23 The absence of a
correlation between pain sensitivity, whole gut transit,
motility, and pelvic floor dyssynergia in the Mertz
study provides persuasive evidence for the indepen-
dence of IBS-C and FC, even though more supportive
studies are needed. (ii) Measure physiological responses
not only under baseline conditions but also after a
provocative stimulus such as a laxative,1 ingestion of a
provocative meal,43–45 or intraluminal distention15;
this may reduce measurement variability. (iii) Incor-
porate differential responses to treatment as part of the
test battery. For example, it is known that antidepres-
sants may be more effective for reducing abdominal
pain than for increasing stool frequency, and that
pelvic floor biofeedback is more effective in consti-
pated patients who exhibit dyssynergic defecation and/
or failure to evacuate a water-filled balloon.41,42,46
Consequently, identifying physiological tests that pre-
dict the response to treatment classes may be very
helpful in separating patients into meaningful sub-
groups.
A limitation of the Lam study1 was the absence of a
credible measure of pain sensitivity. The authors
reported a measure of sensitivity for bloating, defined
as the ratio of the maximum bloating sensation score
following ingestion of a liter of polyethylene glycol to
the total colonic volume, but this does not test the
hypothesis that visceral pain sensitivity is increased in
IBS-C compared to FC. The authors apparently decided
to compute a sensitivity index for bloating only because,
decreased colonic motility and FC. However, other 
studies showed no difference between clinically diag-
nosed groups with IBS-C and FC on these measures.
The study by Lam et al. in this issue1 of the journal 
identifies three additional physiological measures that 
are proposed as biomarkers to separate FC from IBS-C, 
namely the time to first evacuation, volume of water in 
the small intestine, and volume of the ascending colon 
following ingestion of a liter of an osmotic laxative 
(polyethylene glycol). A novel aspect of the Lam study 
is that the authors assessed the response to a provoca-
tive stimulus (ingestion of an osmotic laxative) rather 
than attempting to find physiological differences under 
baseline conditions. The response to a standardized 
provocative stimulus likely increases the signal to 
noise ratio and leads to more reliable separation of 
diagnostic groups.
The physiological significance of the differences in 
small intestinal and colonic volumes following laxa-
tive ingestion is unclear. It seems likely that differ-
ences in colonic and small bowel motility and in time 
to first evacuation contribute to these differences in 
water volume, but differences in the secretion and 
absorption of water by the small intestine and colon 
are also possibilities.
The relatively weak separation between IBS-C and 
FC in the studies reviewed in Table 1 could be 
explained by several factors: (i) In 14 of these 15 
studies, patients were classified into groups based on 
symptom criteria which have been shown to be 
unreliable for separating patients into distinct 
groups.11 Consequently, one would expect some over-
lap between IBS-C and FC when these groups are 
compared on physiological measures. (ii) With the 
exception of the recent study by Lam and colleagues, 
these studies measured physiological differences under 
baseline conditions rather than in response to a 
standardized physiological stimulus such as a laxative 
or a meal. (iii) Most of the studies in Table 1 did not 
distinguish between slow transit constipation and 
functional defecation disorder, but instead assumed 
that FC is a homogeneous disorder. Recognizing that 
subtypes of FC may have different physiological 
mechanisms might improve their discrimination from 
IBS-C.
The studies in Table 1 provide no support for the 
hypothesis that dyssynergic defecation (paradoxical 
contraction or failure to relax pelvic floor muscles 
during defecation) or the related balloon evacuation 
test of the ability to evacuate a water-filled balloon are 
more common in FC than in IBS-C; there is even weak 
evidence for a trend in the opposite direction. Although 
this outcome was unexpected by the reviewers, it is
drug prucalopride improves FC without proven ben-
efits for IBS-C, and pelvic floor biofeedback improves
functional defecation disorder without significant
benefits for slow transit constipation.41 Our review
of the published literature on biomarkers for consti-
pation suggests that whole gut transit time and pain
thresholds have reasonable specificity but modest
sensitivity for differentiating FC and IBS-C, and that
measures of pelvic floor dysfunction are of limited
utility for this purpose. The quest for reliable
biomarkers will likely continue, but the study from
the Nottingham group1 identifies a promising new
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